BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:It is no secret that GLP-1 receptor agonists have transformed 
 the treatment of obesity and diabetes. The past 12 months have seen the G
 LP-1 landscape transform into something truly unrecognizable in previous 
 years\, with the global GLP-1 analogues market valued at US$47.4 billion 
 in 2024.\n\nWith the next frontier of these blockbuster therapeutics well
  on its way to approval\, the GLP-1 field is only going to grow\, with no
 vel combinations\, indications\, and formulations being explored. From MA
 SH to Parkinson's disease\, there is potential for GLP-1s to become a ‘ma
 gic bullet' across healthcare\, only adding to the ever-increasing market
  value.\n\nIn this highly competitive market\, Novo Nordisk and Eli Lilly
  currently lead with first-in-class GLP-1 therapies. However\, the race i
 s now focused on developing 'best-in-class' therapies that offer superior
  efficacy\, particularly in weight loss\, and are delivered through more 
 convenient formats.\n\nDespite significant progress\, challenges remain. 
 From oral formulations to agonist combinations\, from muscle preservation
  to indication expansion\, the question remains: who will be the next com
 pany to bring a GLP-1-based therapeutic to the market?\n\nThe 2nd GLP-1-B
 ased Therapeutics Summit is your dedicated platform for leaders and decis
 ion-makers to connect\, collaborate\, and continue to transform healthcar
 e as we know it through the development of GLP-1s.\n\n&nbsp\;\n\nDate and
  Time: On Tuesday April 29\, 2025 at 9:00 am to Thursday May 1\, 2025 at 
 3:35 pm\n\nVenue details: Hyatt Regency Boston\, One Avenue de Lafayette\
 , Boston\, Massachusetts\, 02111\, United States\n
DTEND:20250501T153500
DTSTAMP:20260512T230903Z
DTSTART:20250429T090000
LOCATION:Hyatt Regency Boston\, One Avenue de Lafayette\, Boston\, Massach
 usetts\, 02111\,
SEQUENCE:0
SUMMARY:It is no secret that GLP-1 receptor agonists have transformed the 
 treatment of obesity and diabetes. The past 12 months have seen the GLP-1
  landsca...
UID:ff3cf94f-750a-4eee-823d-f6be357710b9
END:VEVENT
END:VCALENDAR